Summary Patients with mild asthma may benefit from increasing their inhaled corticosteroid dose, adding a long-acting b 2 -agonist, or both. This study assessed the cost-effectiveness of these options. Patients aged X12 years with mild-to-moderate persistent asthma (n ¼ 1272) were randomised to twice-daily, double-blind treatment with budesonide 100 mg, budesonide 100 mg plus formoterol 4.5 mg, budesonide 200 mg, or budesonide 200 mg plus formoterol 4.5 mg for 12 months. Clinical variables included lung function, number of symptom-free days and number of severe exacerbations. Data on medication use, hospitalisation, visits to health professionals and time off work due to asthma were combined with Swedish unit cost data (1999) to estimate the mean annual cost per patient. Budesonide 200 mg plus formoterol 4.5 mg had the greatest efficacy and effectiveness. Budesonide 200 mg plus formoterol 4.5 mg was both more effective and less costly than budesonide 100 mg plus formoterol 4.5 mg, so a cost-effectiveness ratio was not calculated for this comparison. The cost-effectiveness ratio for budesonide 200 mg plus formoterol 4.5 mg compared with budesonide 200 mg alone was SEK 21 per symptom-free days gained. The combination of budesonide and formoterol in mild-to-moderate persistent asthma improved effectiveness at modest additional cost.
Introduction
Asthma can be categorised as mild intermittent or mild, moderate, and severe persistent, depending on the severity, frequency and persistence of symptoms and the level of medication required. 1 The majority of patients treated in primary care have mild intermittent or mild persistent asthma. 2, 3 However, even patients with mild asthma can be substantially affected by the disease and are at risk from severe exacerbations. 1, 4 In addition to the impact on patients, the cost of asthma is correspondingly high. For example, the annual healthcare costs (direct costs) for asthma treatment were calculated at SEK 1.1 billion in Sweden in 1991 5 and US$ 7.4 billion in the USA in 1998. 6 Productivity or indirect costs (the effect of time lost from work and/or home-making) were also substantial, taking the total costs to SEK 3.0 billion in Sweden 5 and US$ 12.7 billion in the USA. 6 Inhaled corticosteroids can improve asthma control even in mild asthma, 7, 8 and in Sweden it has been found that regions with high use of inhaled corticosteroids also have low rates of asthma hospitalisation. 9 International guidelines recommend inhaled corticosteroids for first-line use in mild persistent asthma. 1 For patients not optimally controlled by low-dose inhaled corticosteroids alone, an additional controller therapy, such as a long-acting b 2 -agonist, or increased corticosteroid dose is recommended. 1 In patients with moderate-to-severe asthma, the risk of asthma exacerbations can be further reduced by adding a long-acting b 2 -agonist, such as formoterol, to inhaled corticosteroid treatment. 10 An economic evaluation using data from this trial found that adding formoterol to an inhaled corticosteroid treatment produced savings in healthcare costs, which partly or completely offset the additional costs of formoterol. 11 The Oxis s (formoterol) and Pulmicort s (budesonide) Turbuhaler s In the Management of Asthma (OPTIMA) clinical trial investigated whether the results in moderate asthma could be extended to patients with milder disease. 3 The clinical analysis examined the effects of adding formoterol to inhaled corticosteroid treatment on the risk of severe exacerbations, asthma symptoms, and lung function. The study included two groups of patients; Group A patients were not receiving corticosteroids prior to the trial, and Group B patients were receiving up to 400 mg per day of inhaled budesonide or its equivalent.
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Treatment regimens for mild persistent asthma may raise concerns over costs, because of the large numbers of patients involved. Therefore, a particular need exists for economic evaluation of treatment regimens in mild asthma. In the OPTIMA study, the Group B patients had mild-to-moderate persistent asthma that was not optimally controlled on budesonide 100 mg twice daily (Group B), and were randomised either to continue on the same dose or to receive one of three step-up treatments; doubling the dose of budesonide; addition of formoterol 4.5 mg; or both. Resource utilisation data were collected alongside the clinical trial, and this paper presents the results of an economic analysis of the three step-up treatments.
Methods

Study design
The OPTIMA clinical study has been fully published elsewhere. 3 In brief, OPTIMA was a randomised, The primary efficacy measures in the clinical trial were the time to first severe exacerbation (defined as hospital admission or emergency treatment for worsening asthma; oral corticosteroid course; 425% decrease in morning peak expiratory flow (PEF) from baseline) and the percentage of days with poorly controlled asthma (defined as days with morning PEF of at least 20% below baseline, where more than two additional reliever medication inhalations were needed, or with awakening due to nocturnal asthma). Secondary efficacy measures included: lung function; percentage of days with symptoms; number of reliever inhalations required; percentage of nights with asthma awakenings; and number of severe exacerbations per patient per year.
Cost and effectiveness assessments
The primary effectiveness variable in the economic evaluation was the number of symptom-free days (SFD) per year. The number of severe exacerbations per patient per year was also measured. The SFD has been recommended as an outcome measure in guidelines for economic evaluation in asthma, 12 and severe exacerbations have been related to increases in cost. 4 Utilisation of healthcare resources (e.g. days in hospital, visits to a physician, etc.) and days on which patients were unable to work (employment or home-making) were recorded in case-report forms. Medication use (study medication, reliever medication, and other medication required after the first severe exacerbation) was also recorded.
The cost for each patient in the trial was estimated by multiplying the resource use data by the cost per unit for each type of resource, and adjusted for the randomised period. Unit cost data were taken from Swedish sources in 1999 prices and are shown in Table 1 . Where data were taken from a source published prior to 1999, they were adjusted by inflation to 1999 prices. pMDI ¼ pressurised metered dose inhaler.
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The cumulative costs and effectiveness during the randomised period were estimated for each patient individually and normalised to 1 year. This differs slightly from the method used in the clinical paper, 3 where the clinical outcome variables were calculated on a group basis for the randomised period. It was important that both the cost and effectiveness data in the economic evaluation were estimated in the same way, and that costs and effectiveness over a specific time period were considered in the analysis. The clinical analysis was based on exposure time, while the economic analysis was based on individual data for the study period of 12 months. If this approach is not used, the economic analysis would be biased. Furthermore, a small number of patients did not provide a complete set of economic resource use data and were excluded from the economic analysis. For these reasons, the effectiveness data in the economic analysis differ slightly from those presented in the clinical paper. 
Cost-effectiveness
An incremental cost-effectiveness ratio (ICER) compares one treatment group with another, by taking the difference in cost between the two groups and dividing it by the difference in effectiveness between the two groups. This provides a measure of the additional cost required to gain a given unit of improvement in effectiveness.
In situations where there are more than two treatments to compare, it is possible to rule out any treatment that clearly has a less beneficial cost-effectiveness profile than an alternative treatment, i.e., at least one other treatment has higher effectiveness and lower cost. In such a case the treatment with the less beneficial profile is said to be 'dominated' by the treatment(s) with higher effectiveness and lower cost, and can be excluded from further analysis. 20 This simplifies the analysis and reduces the number of comparisons needed.
The cost analysis was conducted from the perspective of a healthcare payer (total healthcare costs only) and from a societal perspective (healthcare costs and productivity costs). Incremental cost-effectiveness ratios were calculated from a societal perspective.
A sensitivity analysis was conducted by applying unit costs (prices) from the UK and Spain to the entire patient population. This did not significantly change the overall results, and thus indicates that the overall results are robust.
The study was not powered to detect differences in cost; however observed differences in cost and effectiveness were tested for statistical significance using a parametric test.
Results
Clinical results
The clinical outcome results for the four treatment groups are summarised in Table 2 . All three step-up treatments showed improvements compared with budesonide 100 mg alone. Budesonide 200 mg reduced the percentage of days with symptoms compared with budesonide 100 mg ( Table 2) . Budesonide 100 mg plus formoterol 4.5 mg was significantly more effective than budesonide 200 mg alone in reducing the risk of a severe exacerbation or a poorly controlled asthma day 3 and in improving FEV 1 , morning PEF and the number of severe exacerbations per year ( Table 2 ). The magnitude of the improvement with budesonide 200 mg plus formoterol 4.5 mg was larger than that seen with budesonide 100 mg plus formoterol 4.5 mg in all parameters, although these differences were not tested for statistical significance 3 (Table 2) .
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Thus, clinical efficacy increased in the order: budesonide 100 mg alone, budesonide 200 mg alone, budesonide 100 mg plus formoterol 4.5 mg, budesonide 200 mg plus formoterol 4.5 mg.
Economic results
The results for the outcome measures used in the economic evaluation are shown in Table 3 . As described in the Methods section, these data differ slightly from the clinical outcomes data shown in Table 2 .
The use of resources by each group is shown in Table 4 . The healthcare costs for each group are shown in Table 5 and Fig. 1 . As would be expected, all three step-up treatments were associated with increased study-medication costs compared with budesonide 100 mg alone. However, the patients receiving budesonide 100 mg plus formoterol 4.5 mg or budesonide 200 mg plus formoterol 4.5 mg required substantially fewer days in hospital than either of the budesonide-only groups (Table 4) , resulting in a reduction in the costs of healthcare resources (Table 5 ; Fig. 1 ). This, combined with reductions in the costs of reliever and other medications, partly offset the additional cost of formoterol. Increasing the dose of budesonide without adding formoterol was associated with a smaller increase in study-medication costs, but without the offsetting reduction in hospital days or healthcare resources seen in the formoterol groups. The number of days missed from work was also substantially reduced in patients receiving either budesonide 100 mg plus formoterol 4.5 mg or budesonide 200 mg plus formoterol 4.5 mg ( Table 4 ). The reduction in time off work has an intrinsic value in itself in reduced disruption to patients' lives. A monetary value for time off work (productivity cost) can also be estimated, and is shown in Table 5 and Fig. 1 Tests conducted to compare the step-up alternatives with formoterol to the step-up alternative with budesonide alone. No P-values calculated for study-medication cost, as this was driven by the study protocol; no statistically significant differences in total costs between any of the groups; totals may not add due to rounding. the reduction in the number of days off work, almost completely offset the additional cost of formoterol compared with budesonide 200 mg ( Table 5 ). When the savings in productivity costs were included (taking a societal perspective), there were no statistically significant differences in total costs between any of the treatment groups, and the three step-up treatment groups were numerically almost identical (Table 5 ; Fig. 1 ).
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Cost-effectiveness
Comparing the three step-up treatments, budesonide 100 mg plus formoterol 4.5 mg had the highest total cost (Table 5 ). However, it was not the most effective treatment, as budesonide 200 mg plus formoterol 4.5 mg provided more SFD per year (Table 3 ). Therefore, since budesonide 100 mg plus formoterol 4.5 mg was both more expensive and less effective than budesonide 200 mg plus formoterol 4.5 mg, it clearly could not provide the best 'value for money'. In this situation, budesonide 100 mg plus formoterol 4.5 mg is said to be 'dominated', and was excluded from the analysis. This left budesonide 200 mg alone to be compared with budesonide 200 mg plus formoterol 4.5 mg in the cost-effectiveness analysis. Budesonide 200 mg plus formoterol 4.5 mg provided more SFD per year (Table 3 ) but was associated with higher costs (Table 5) , i.e., it was both more effective and more expensive than budesonide 200 mg alone. The ICER for this comparison was SEK 21 per SFD gained.
Discussion
International guidelines recommend a stepwise approach to asthma treatment, increasing controller therapy until optimal control of asthma is achieved. 1 The present study provides data on the economic effects of three potential options for stepping up treatment. The study patients would be candidates for step-up therapy, as they had to show signs of sub-optimal control during the run-in period of treatment with budesonide 100 mg twice daily. The results show that treatment with formoterol plus budesonide improved asthma control, and was more effective than doubling the corticosteroid dose in improving FEV 1 , improving PEF and reducing the number of severe exacerbations per year 3 ( Table 2 ). Adding formoterol 4.5 mg to either dose of budesonide significantly increased the time until the first severe exacerbation, reduced the number of days with poorly controlled asthma symptoms, reduced the need for reliever medication and improved lung function (FEV 1 and PEF). 3 These results show that even patients with mild asthma can obtain significant clinical benefit by stepping up therapy from a low dose of inhaled corticosteroids alone, and are consistent with the earlier findings of clinical benefit obtained by adding formoterol to budesonide treatment in patients with moderate asthma. 10 The effectiveness measures used in the economic analysis showed a similar pattern. Budesonide 200 mg plus formoterol 4.5 mg provided the largest number of SFD per year, and the greatest reduction in the number of severe exacerbations per year (Table 3) .
These clinical benefits were obtained at a modest additional cost. Combination treatment with budesonide and formoterol was associated with reductions in the costs of reliever medication, other medications and healthcare resources (such as hospitalisation and visits to healthcare professionals), at either dose of budesonide, and these savings offset most of the additional cost of formoterol treatment. When productivity costs were also included, there were no significant differences in total costs between any of the treatment groups.
Budesonide 100 mg plus formoterol 4.5 mg was associated with the highest total cost, but was not the most effective treatment. The reason that the costs were higher for 100 mg plus formoterol 4.5 mg than for budesonide 200 mg plus formoterol 4.5 mg was basically the lower productivity costs in the latter group (likely to result from the higher efficacy in that group). Since budesonide 200 mg plus formoterol 4.5 mg was both more effective and less expensive, budesonide 100 mg plus formoterol 4. For comparison, a study using economic modelling techniques calculated that using inhaled corticosteroid treatment in patients with mild-tomoderate persistent asthma cost US$ 7.50 per SFD gained, compared with using rapid relief medication alone. 25 This is equivalent to SEK 67 at the November 2002 exchange rate of US$ 1 ¼ SEK 8.99. Our finding of SEK 21 per SFD in the present study thus compares favourably with Paltiel et al. 21 although direct comparisons between studies with differing methodology should be made with caution.
The SFD measure is asthma-specific and thus cannot be used to make economic comparisons between treatments for asthma and treatments for other diseases. Such comparisons would require data using a general outcome measure, such as quality-adjusted life-years (QALYs).
The reductions in days in hospital and days off work observed in the patients receiving formoterol and budesonide have an intrinsic value, as well as their monetary value. Hospitalisation is disruptive and may also be distressing or frightening for patients and their families. Time lost from work or education may impair future career prospects. The adverse impact of asthma, especially poorly controlled asthma, on patients' lives may be considerable. For example, in a population-based survey conducted in the USA, 22% of patients with poorly controlled asthma felt that their disease had interfered with their career plans, and 44% felt that it interfered with their social lives. 22 Outcomes such as these are not generally captured by conventional measures of clinical status, and cannot be inferred from them, 23 but are clearly of importance to patients. Improved asthma control provides important intangible benefits by allowing patients to lead fuller lives with less disruption due to asthma symptoms. For example, in the US survey mentioned above, the percentages of patients with controlled asthma who said the disease interfered with their career plans or social lives were 10% and 5%, respectively, significantly lower than in the patients with poorly controlled asthma. 22 The improvements in asthma control (more SFD per year, fewer severe exacerbations per year) observed in the patients taking combined formoterol and budesonide in the present study are likely to represent valuable intangible benefits, but these benefits were not quantified.
When conducting an economic evaluation based on a multinational clinical study, at least two difficulties exist: (1) healthcare utilisation and treatment patterns differ between countries, and (2) unit costs (prices) differ. 24, 25 Selecting the patients from one individual country is often not feasible due to the power of the study. Thus, data is most often pooled across all countries and are then multiplied with the unit costs from one country. Pooling data is an area of current health economic research, since variations in healthcare systems and treatment patterns may influence the policy implications for individual countries based on the overall results. There exist some statistical techniques for how to deal with this variability, but a preferred approach does not yet exist, and these complex issues were beyond the scope of the present study. 26 For this economic analysis, we chose to use Swedish unit cost data because the information is readily available, health economic data is of great interest in healthcare decisionmaking in Sweden, and because Sweden contributed with many patients in this study. Clearly, some caution should be exercised when applying these results to other countries (especially if there is a great difference in unit cost structure).
The results of the present study are consistent with those reported by an economic analysis of data from a clinical trial in patients with moderate asthma. 11 In that study, the addition of formoterol to budesonide improved effectiveness, reduced total costs in Sweden, and was clearly costeffective. 11 This result, derived from the clinical study by Pauwels et al. 10 was unexpected at the time and has influenced treatment guidelines and healthcare policy. Formoterol combined with an inhaled corticosteroid is now an established component of therapy for patients with moderate asthma. 1 The present study and the clinical trial on which it is based 3 have shown that the benefits of combined budesonide and formoterol treatment can also be extended to patients with milder persistent asthma.
In summary, combined treatment with budesonide 200 mg and formoterol 4.5 mg in patients with mild-to-moderate persistent asthma improved asthma control compared with budesonide 200 mg alone at a modest increase in cost, and the costeffectiveness of treatment compared favourably with results reported in other studies. These findings indicate that budesonide and formoterol could provide a cost-effective treatment option in patients with mild-to-moderate persistent asthma who would benefit from stepping-up treatment.
